The potential role of glucagon‐like peptide‐1 or its analogues in enhancing glycaemic control in critically ill adult patients

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2011-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2010.01311.xPMID 21199263
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Surviving sepsis campaign : international guidelines for management of severe sepsis and septic shock

  2013cited by this paper
• Ill Adults: A Meta-analysis Benefits and Risks of Tight Glucose Control in Critically

  2010cited by this paper
• Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia*

  2010cited by this paper
• Glucose Measurement in the Operating Room: More Complicated than It Seems

  2010cited by this paper
• What Makes Tight Glycemic Control Tight? The Impact of Variability and Nutrition in Two Clinical Studies

  2010cited by this paper
• Faculty of 1000 evaluation for Review article: glucose measurement in the operating room: more complicated than it seems.

  2010cited by this paper
• Efficacy and safety of an insulin infusion protocol during and after cardiac surgery.

  2010influential reference
• Hypoglycemia and outcome in critically ill patients.

  2010cited by this paper
• Glucose variability is associated with intensive care unit mortality*

  2010cited by this paper
• Toward understanding tight glycemic control in the ICU: a systematic review and metaanalysis.

  2010cited by this paper
• Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety.

  2009cited by this paper
• Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study.

  2009cited by this paper
• Métabolisme du glucose en situation pathologique aiguë

  2009cited by this paper
• Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

  2009cited by this paper
• Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary*

  2009cited by this paper
• Glycaemic dysregulation in nondiabetic patients after major lower limb prosthetic surgery.

  2009cited by this paper
• Unraveling the science of incretin biology.

  2009cited by this paper
• Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data

  2009cited by this paper
• [Glucose metabolism in acute critical situation].

  2009cited by this paper
• American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control

  2009cited by this paper
• A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study

  2009cited by this paper
• Unraveling the science of incretin biology.

  2009cited by this paper
• The incretin system and its role in type 2 diabetes mellitus.

  2009cited by this paper
• Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.

  2009cited by this paper
• The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study

  2009cited by this paper
• The impact of early hypoglycemia and blood glucose variability on outcome in critical illness

  2009cited by this paper
• Intensive versus conventional glucose control in critically ill patients.

  2009influential reference
• Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction.

  2009cited by this paper
• Full Accounting of Diabetes and Pre-Diabetes in the U.S. Population in 1988–1994 and 2005–2006

  2009cited by this paper
• The impact of the severity of sepsis on the risk of hypoglycaemia and glycaemic variability

  2008cited by this paper
• Glycemic variability: A strong independent predictor of mortality in critically ill patients*

  2008cited by this paper
• Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

  2008cited by this paper
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes.

  2008cited by this paper
• Intensive insulin therapy and pentastarch resuscitation in severe sepsis.

  2008cited by this paper
• Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials.7.

  2008cited by this paper
• Glucose variability and mortality in patients with sepsis*

  2008cited by this paper
• Prevalence of elevated hemoglobin A1c among patients admitted to the hospital without a diagnosis of diabetes.

  2008cited by this paper
• Intensive Insulin Therapy in Critical Care

  2007cited by this paper
• Impact of intensive insulin therapy on neuromuscular complications and ventilator dependency in the medical intensive care unit.

  2007cited by this paper
• Severe hypoglycemia in critically ill patients: Risk factors and outcomes*

  2007cited by this paper
• Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008

  2007cited by this paper
• Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.

  2007cited by this paper
• Comparison of a nurse initiated insulin infusion protocol for intensive insulin therapy between adult surgical trauma, medical and coronary care intensive care patients

  2007influential reference
• Tight Glycemic Control in Critically Injured Trauma Patients

  2007cited by this paper
• Biology of incretins: GLP-1 and GIP.

  2007cited by this paper
• The Hyperglycemia: Intensive Insulin Infusion in Infarction (HI-5) study: a randomized controlled trial of insulin infusion therapy for myocardial infarction.

  2006cited by this paper
• Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project.

  2006cited by this paper
• Towards a feasible algorithm for tight glycaemic control in critically ill patients: a systematic review of the literature

  2006cited by this paper
• Glycemic control, diabetic status, and mortality in a heterogeneous population of critically ill patients before and during the era of intensive glycemic management: six and one-half years experience at a university-affiliated community hospital.

  2006influential reference
• Intensive Insulin Therapy in Mixed Medical/Surgical Intensive Care Units

  2006cited by this paper
• Evaluation of nursing work effort and perceptions about blood glucose testing in tight glycemic control.

  2006cited by this paper
• Predisposing factors for hypoglycemia in the intensive care unit*

  2006influential reference
• Variability of Blood Glucose Concentration and Short-term Mortality in Critically Ill Patients

  2006cited by this paper
• Enteral nutrition versus glucose-based or lipid-based parenteral nutrition and tight glycaemic control in critically ill patients.

  2006cited by this paper
• Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.

  2006cited by this paper
• Exenatide: a new option for the treatment of type 2 diabetes.

  2006cited by this paper
• Impact of admission hyperglycemia on hospital mortality in various intensive care unit populations*

  2005cited by this paper
• Glycemic control in the intensive care unit: why we should wait for NICE-SUGAR.

  2005cited by this paper
• Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.

  2005cited by this paper
• Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction: Implications for Patients With and Without Recognized Diabetes

  2005cited by this paper
• Influence of individual characteristics on outcome of glycemic control in intensive care unit patients with or without diabetes mellitus.

  2005cited by this paper
• Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes.

  2005cited by this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cited by this paper
• Intravenous insulin infusion therapy: indications, methods, and transition to subcutaneous insulin therapy.

  2004cited by this paper
• Does enteral nutrition compared to parenteral nutrition result in better outcomes in critically ill adult patients? A systematic review of the literature.

  2004cited by this paper
• Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults

  2004cited by this paper
• Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit.

  2004cited by this paper
• Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes.

  2004cited by this paper
• Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

  2004cited by this paper
• Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials.

  2004cited by this paper
• Tight Glycemic Control in Diabetic Coronary Artery Bypass Graft Patients Improves Perioperative Outcomes and Decreases Recurrent Ischemic Events

  2004cited by this paper
• Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

  2004cited by this paper
• Nutrition support in the critical care setting: current practice in canadian ICUs--opportunities for improvement?

  2003cited by this paper
• Validation of a glucose–insulin–potassium infusion algorithm in hospitalized diabetic patients

  2003cited by this paper
• Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting.

  2003cited by this paper
• Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

  2003cited by this paper
• Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients.

  2003influential reference
• Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

  2003cited by this paper
• Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control*

  2003cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2003cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Intensive insulin therapy in critically ill patients.

  2002influential reference
• Description and evaluation of a glycemic management protocol for patients with diabetes undergoing heart surgery.

  2002cited by this paper
• Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes.

  2002cited by this paper
• Insulin subcutaneous application vs. continuous infusion for postoperative blood glucose control in patients with non-insulin-dependent diabetes mellitus.

  2002cited by this paper
• Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats.

  2002cited by this paper
• Intensive insulin treatment reduces transient ischaemic episodes during acute coronary events in diabetic patients.

  2002cited by this paper
• A prospective survey of nutritional support practices in intensive care unit patients: What is prescribed? What is delivered?

  2001cited by this paper
• Intensive insulin therapy in critically ill patients.

  2001cited by this paper
• Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes.

  2001cited by this paper
• The control of blood glucose in the critical diabetic patient: a neuro-fuzzy method.

  2001cited by this paper
• Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.

  2001cited by this paper
• Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.

  2001cited by this paper
• Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.

  2000cited by this paper
• Management of nutrition in European intensive care units: results of a questionnaire

  1999cited by this paper
• Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycemia: the Glucose Insulin in Stroke Trial (GIST).

  1999cited by this paper
• Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

  1999cited by this paper
• Normalization of fasting glycaemia by intravenous GLP‐1 ([7‐36 amide] or [7‐37]) in Type 2 diabetic patients

  1998cited by this paper
• Grains or veins: is enteral nutrition really better than parenteral nutrition? A look at the evidence.

  1998cited by this paper

• Stress-Induced Hyperglycemia: Consequences and Management

  2022cites this paper
• Transcriptome-wide analysis of PGC-1α–binding RNAs identifies genes linked to glucagon metabolic action

  2020cites this paper
• A New Activator of Hepatocyte CaMKII in Fasting and Type 2 Diabetes

  2018cites this paper
• Exogenous glucagon-like peptide-1 attenuates glucose absorption and reduces blood glucose concentration after small intestinal glucose delivery in critical illness.

  2017cites this paper
• Glucagon's effect on liver protein metabolism in vivo.

  2017cites this paper
• Dapagliflozin suppresses glucagon signaling in rodent models of diabetes

  2017cites this paper
• Postprandial Suppression of Glucagon Secretion: A Puzzlement

  2017cites this paper
• Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver–α-Cell Axis

  2017cites this paper
• Enterohormones and the Response to Critical Illness

  2016cites this paper
• Neuroinflammatory and autonomic mechanisms in diabetes and hypertension.

  2016cites this paper
• The incretin effect in critically ill patients: a case–control study

  2015influential citation
• The effects of TNF-α on GLP-1-stimulated plasma glucose kinetics.

  2015cites this paper
• Pathway to Artificial Pancreas Systems Revisited: Moving Downstream

  2015cites this paper
• Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.

  2015cites this paper
• Perioperative catabolism

  2015cites this paper
• Quantification of the Glycemic Response to Microdoses of Subcutaneous Glucagon at Varying Insulin Levels

  2014cites this paper
• I Prostanoid Receptor–Mediated Inflammatory Pathway Promotes Hepatic Gluconeogenesis Through Activation of PKA and Inhibition of AKT

  2014cites this paper
• Incretins and the intensivist: what are they and what does an intensivist need to know about them?

  2014cites this paper
• Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study.

  2014cites this paper
• GCN2 regulates the CCAAT enhancer binding protein beta and hepatic gluconeogenesis.

  2013cites this paper
• Dysglycaemia in the critically ill – significance and management

  2013cites this paper
• Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism

  2012cites this paper